I simply do not understand the logic of any of the explanations coming from Merck and their subsidiaries.

Why there is a shortage is not explained, why it should affect both branded and generic, why CR is singled out right now though the initial EU notice included all variations, and why it should be 'world wide'. There has been no implication of shortage of raw material, or problems with distribution, only a vague statement relating to 'source of supply' changes and 'timelines needed to obtain regulatory approvals' (world wide???) ......... but they KNOW that it is an essential replacement drug, not a palliative. Would they not have taken care to ensure a continuing supply if they were shifting production or some such? The more I see this story the less sense it makes.

And no comment ANYWHERE from any of the orgs that represent patients and/or their interests, though it has been announced on three continents.....

We are not just patients but consumers as well.

Perhaps patients are due some answers that make the real picture clearer.